Form 8-K - Current report:
SEC Accession No. 0001104659-24-122099
Filing Date
2024-11-22
Accepted
2024-11-22 16:09:16
Documents
13
Period of Report
2024-11-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2429290d1_8k.htm   iXBRL 8-K 31190
  Complete submission text file 0001104659-24-122099.txt   206833

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cara-20241119.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cara-20241119_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cara-20241119_pre.xml EX-101.PRE 22375
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2429290d1_8k_htm.xml XML 3684
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 241489817
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)